For the last several years, radiopharmaceuticals have enjoyed one of the strongest narratives in oncology: find a molecular target, image it, determine whether the patient expresses it, attach a therapeutic radionuclide to a targeting molecule and deliver radiation directly to cancer cells. It is an elegant idea, and the pharmaceutical industry has responded accordingly. Billions of dollars have flowed into radiopharmaceutical acquisitions, isotope production, manufacturing facilities and clinical pipelines as companies race to build the infrastructure for what many believe will become a major new pillar of cancer treatment.
This week, however, another form of precision oncology crossed an important threshold. Merck and Moderna announced that the Phase 3 INTerpath-001 trial of intismeran autogene, their individualized neoantigen therapy, in combination with Keytruda met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected Stage IIB-IV melanoma. The companies said the combination produced statistically significant and clinically meaningful improvements over Keytruda alone.
According to Merck and Moderna, this is the first positive Phase 3 readout for an individualized neoantigen therapy and an mRNA-based cancer therapy. The treatment is designed using the unique mutational fingerprint of an individual patient's tumor, potentially validating an extraordinarily personalized approach to cancer treatment at Phase 3.
That is an important moment for oncology. But it doesn't necessarily mean radiopharma has been outflanked by a more personalized technology. It may instead force the industry to recognize something more interesting: radiopharma already has its own version of personalized cancer treatment.
Intismeran autogene approaches cancer by analyzing the genetic characteristics of an individual patient's tumor and creating an individualized therapy containing selected neoantigens. The objective is to train the patient's immune system to recognize cancer cells carrying mutations specific to that tumor.
It is personalization at perhaps its most literal: manufacture a medicine around the biological characteristics of one patient's cancer.
Radiopharmaceutical therapy approaches the same problem differently. Instead of necessarily manufacturing a different therapeutic molecule for every patient, theranostics can use molecular imaging to determine whether a particular biological target is present throughout an individual's disease. If it is, a therapeutic molecule directed at that target can carry radiation directly to those cancer cells.
One approach interrogates the tumor genetically. The other interrogates it molecularly and spatially. Both, however, are trying to answer essentially the same question: what is unique about this patient's cancer, and how can we exploit it?
That distinction matters because personalized medicine is often discussed as though the medicine itself must be individually manufactured. Nuclear medicine suggests that treatment can be personalized in other ways; through patient selection, molecular imaging, treatment location and radiation dose.
And there is another company that makes this argument even more interesting.
OncoBeta sits outside the systemic radioligand therapies currently attracting most of the pharmaceutical industry's attention, but its technology provides a useful example of how broad the concept of personalized radionuclide treatment could eventually become.
The company's Rhenium-SCT uses the beta-emitting isotope rhenium-188 to treat certain non-melanoma skin cancers, including basal cell and squamous cell carcinomas. Rather than injecting a radiopharmaceutical into the bloodstream and relying on a targeting molecule to find cancer cells throughout the body, the radioactive compound is applied precisely over the area being treated. OncoBeta describes Rhenium-SCT as a personalized therapy applied only to the required treatment area, with Re-188 beta particles penetrating only a few millimeters into tissue.
That is an entirely different implementation of the same basic precision-oncology philosophy.
Moderna personalizes treatment around the genetic fingerprint of the tumor. Conventional theranostics can personalize treatment around molecular target expression revealed by imaging. OncoBeta can personalize radiation around the physical location and characteristics of an accessible tumor.
The treatment doesn't need to search throughout the body for its target because clinicians already know where the target is. Instead, the challenge becomes delivering radiation precisely where it is needed while minimizing unnecessary exposure to surrounding tissue.
And the clinical evidence is notable. In February 2026, OncoBeta reported final two-year results from its international Phase IV EPIC-Skin study. Among 171 evaluable tumors in 130 patients with 24 months of follow-up, Rhenium-SCT achieved a 94.7% complete response rate after a single treatment session. The reported complete response rate was 93.9% for basal cell carcinoma and 97.5% for squamous cell carcinoma.
This isn't mRNA personalized medicine. It isn't conventional theranostics either. It is precision radiation, and that may ultimately prove to be a much larger category.
The Moderna-Merck result therefore raises a bigger question than whether mRNA cancer vaccines could compete with radiopharmaceuticals. What exactly do we mean by personalized cancer treatment?
If personalization means manufacturing a completely different drug for every patient's tumor, individualized neoantigen therapies have an obvious conceptual advantage. But if personalization means selecting and adapting treatment according to the characteristics of an individual patient's disease, radiopharma suddenly looks very different.
Nuclear medicine can personalize treatment at several levels simultaneously. Molecular imaging can determine whether a therapeutic target is expressed and show where that target exists throughout the body. Dosimetry can potentially help determine how much radiation individual tumors and normal organs actually receive. Radionuclides with different physical properties can be matched to different therapeutic objectives, while localized approaches such as Rhenium-SCT demonstrate that radiation can also be directed toward specific accessible lesions.
The medicine doesn't necessarily have to be manufactured uniquely for every patient because the way the medicine is selected, delivered and dosed can itself become personalized. And that could be one of radiopharma's most underappreciated advantages.
Conventional theranostics brings something particularly unusual to this emerging personalized oncology model: it can often see what it intends to treat.
A diagnostic radiopharmaceutical can provide information about target expression across disease sites throughout the body before therapeutic radiation is delivered. That creates the possibility of selecting patients based on molecular imaging rather than relying exclusively on tissue obtained from one biopsy. It can also create a feedback loop in which clinicians image the disease, select the patient, treat the disease, image again, measure response and potentially adjust subsequent treatment. That combination of diagnostics and therapeutics is one reason theranostics has become such an important concept in precision medicine.
Compare that with the individualized cancer vaccine model. Tumor sequencing provides extraordinarily detailed biological information, but it doesn't necessarily show where every cancer cell expressing those characteristics is located throughout the body.
Molecular imaging can provide a different type of information: a whole-body map of biological target expression.
These capabilities are not mutually exclusive. In fact, combining them could ultimately be much more powerful than choosing between them.
There is another aspect of the OncoBeta model that deserves attention because it reaches beyond personalization and into one of radiopharma's biggest commercial challenges: isotope logistics.
OncoBeta also produces tungsten-188/rhenium-188 generators. Tungsten-188 serves as the longer-lived parent isotope and decays into therapeutic Re-188, which can be extracted for use. The company's generator systems are designed to support access to Re-188 for clinical and research applications, with systems available at activities up to 150 GBq of W-188.
That creates an interesting model for nuclear medicine. Instead of producing every therapeutic isotope at a centralized facility and repeatedly transporting short-lived material through a complex distribution network, generator systems can move part of the isotope-production capability closer to the point of care.
Generator systems are hardly new to nuclear medicine, but the combination is noteworthy. OncoBeta effectively brings together isotope availability, a therapeutic radionuclide, specialized application technology and an individualized treatment approach within the same platform.
That is another reminder that the future of radiopharma may not look exclusively like today's Lu-177 and Ac-225 industry.
There is still a competitive warning embedded in Moderna's success. Many of today's approved radiopharmaceutical therapies are used in patients with advanced disease. But the enormous opportunity driving investment into radiopharma is the possibility of moving targeted radiation earlier. If radiopharmaceutical therapies can move from late-line metastatic disease into earlier treatment, combination regimens and potentially adjuvant settings, their addressable patient populations become dramatically larger.
The problem is that virtually every other major oncology modality wants the same territory. Antibody-drug conjugates are moving earlier. Bispecific antibodies are moving earlier. Immunotherapies are moving earlier. Cell therapies are looking for ways to expand beyond their existing niches. Now personalized cancer vaccines have produced a positive Phase 3 result in an adjuvant melanoma setting.
Radiopharma therefore isn't simply competing against other radiopharma companies. It is competing against the entire oncology innovation ecosystem for positions in future standards of care.
If an individualized cancer vaccine prevents recurrence before metastatic disease develops, some patients who might eventually have become candidates for later-line radiopharmaceutical therapy may never reach that point. If an antibody-drug conjugate produces superior outcomes earlier in treatment, targeted radionuclide therapy could be pushed further down the sequence.
Infrastructure alone will not protect radiopharma from that competition. The billions being invested in isotope capacity, hot cells, cyclotrons, reactors, manufacturing facilities and distribution networks are necessary, but they do not guarantee clinical relevance. Ultimately, biology and patient outcomes determine where a therapy belongs.
There is another possibility, and it could be far more important. Radiopharmaceutical therapy may eventually become part of the personalized cancer-treatment architecture that technologies such as intismeran are helping create.
Radiation does more than simply damage DNA and kill cancer cells. It can also alter the tumor microenvironment and influence immune responses, which is one reason researchers have spent years investigating combinations of radiation and immunotherapy. The scientific story remains complicated because radiation can stimulate immune responses but can also suppress them depending on dose, timing, treatment volume and other factors.
Radioligand therapy adds another dimension because it can potentially carry radiation to multiple tumor sites throughout the body. Researchers are already investigating combinations involving radiopharmaceutical therapy and immunotherapy, although important questions around timing, radionuclide characteristics, toxicity and immune-cell damage remain unresolved.
Now imagine those technologies as parts of the same treatment architecture rather than competing silos.
Tumor sequencing identifies the mutations distinguishing an individual's cancer. Molecular imaging shows where disease is located and whether particular therapeutic targets are expressed. Targeted radionuclide therapy attacks disease throughout the body. Personalized dosimetry helps optimize radiation exposure. Individualized neoantigen therapy trains the immune system to recognize tumor-specific mutations, while checkpoint inhibition helps sustain the immune response.
For accessible localized tumors, approaches such as OncoBeta's demonstrate yet another possibility: deliver radionuclide therapy directly to the lesion. And in that world, there may be no single technological winner. The winner is the combination that produces the best patient outcome.
This is ultimately why Moderna's achievement may be good news for radiopharma. It validates the larger movement toward cancer treatment becoming increasingly specific to the characteristics of an individual patient's disease. Radiopharma doesn't sit outside that movement. It may represent another branch of it.
Personalization can be genetic, with treatment designed around mutations within an individual tumor. It can be molecular, with imaging determining whether and where a therapeutic target is expressed. It can be spatial, directing radiation toward the precise location of disease. And it can be dosimetric, adapting radiation exposure according to the patient, tumor burden and normal-organ tolerance.
OncoBeta makes that broader definition particularly tangible. Its Rhenium-SCT isn't personalized because a new molecule is manufactured for every patient. It is personalized because radiation is applied precisely to the treatment area, using a radionuclide whose physical characteristics are suited to superficial disease. The company's own description emphasizes that precise, localized model.
That suggests something important about the future of this industry. Perhaps radiopharma is only one part of a much larger precision-radiation economy. Systemic radioligands, localized radionuclide therapies, theranostics, generator-based treatments, image-guided therapies and personalized dosimetry could all sit within the same broader ecosystem.
The Moderna-Merck result should not frighten the radiopharmaceutical industry. It should expand the industry's thinking about what personalized medicine actually means. Cancer treatment appears to be moving toward an increasingly individualized model, but there may not be one technological path to get there.
Moderna is personalizing medicine around the genetic characteristics of a patient's tumor. Theranostics can personalize treatment around molecular expression revealed by imaging. OncoBeta demonstrates another approach, using Re-188 to deliver highly localized treatment to accessible tumors. Dosimetry adds another layer by potentially adapting radiation delivery to the individual patient.
These are not necessarily competing philosophies. They may be different layers of what eventually becomes a patient-specific oncology system.
That possibility changes the way radiopharma should interpret the rise of personalized cancer vaccines. The question isn't whether mRNA replaces targeted radiation or targeted radiation defeats mRNA. The more consequential question is which technologies become indispensable components of future cancer care and which combinations deliver outcomes good enough to change standards of care.
Radiopharma has spent the last several years proving that radionuclides can become important oncology drugs. The next opportunity may be considerably larger: proving that precision radiation can become one of the fundamental tools through which cancer treatment itself becomes personalized. Moderna may have just validated one path toward personalized oncology. Radiopharma has another.
